Research Using Health One
Ryan, D., et al. (2010). Nonsurgical
Weight Loss for Extreme Obesity in Primary Care
Settings. Arch Intern Med. 170(2):146-154.
LOSS STUDY: The State of Louisiana, through the
State Office of Group Benefits, tested a variety
of treatment protocols for weight management for
efficacy to lower body weight, improve health
parameters, and serve as a cost-saving approach,
both for the individual and for the third party
payer. This study started in July, 2005. The study
used HEALTH ONE plus "intensive counseling"
as one of the treatment arms. The principal investigator
was Dr. Donna Ryan from the Pennington Biomedical
Research Institute (which is affiliated with Louisiana
State University Medical Center).
de Jonge L., Moreira E. A.M., Martin C.K., Ravussin
E. (2010) Impact of Six-month Caloric Restriction
on Autonomic Nervous System Activity in Healthy,
Overweight Individuals. Obesity 18: 414-416.
This study explored the effects of calorie restriction
on the relative function of the sympathetic nervous
system, and the parasympathetic nervous system,
an independent risk factor of cardiovascular disease.
Noe, M. A., et al. (2010). The Health Improvement
Project (HIP): A Report on the Outcome of an Intensive
Medical Intervention for Class III Obesity. Obesity
18(2):148.
HIP STUDY : From the University of Buffalo, Center
for Preventive Medicine. It compared four approaches
for medical management of obesity – 1) intensive
diet, behavioral therapy and medication, 2) intensive
diet and behavioral treatment, 3) diet, behavioral
therapy and medication and 4) diet and behavioral
therapies. Results presented in a poster session
at The Obesity Society annual meeting in 2010.
Greenway, F., Tomayko, K., et al. BARIA Study.
(Initiated September 2009). Comparison of Longer
Term Outcomes of Weight Loss between Use of Low
Calorie Meal Replacement (HEALTH ONE) and Bariatric
Surgical Techniques. Pennington Center For Biomedical
Research, Baton Rouge, LA.
http://clinicaltrials.gov/ct2/show/NCT00936130
Carney, D., Schultz, S., Carney, S. (2009). Medical
Obesity Treatment: Long-Term Success in a Primary
Care Setting. J Diabetes Sci. Technol. 3(6):1524-6.
This publication detailed clinical results from
917 patients on an HNT weight management program
from 1991 to 2004. Weight loss was 16% ±
8.4% (17.5 ± 10.7 kg) after 14.2 weeks.
After 11.9 months in maintenance, weight loss
was still 16.4% ± 8.7% (18.4 ± 11.4
kg).
Larson-Meyer D.E., Redman L.M., Heilbronn L.K.,
Martin C.K., Ravussin E. (2009). Calorie Restriction
with or without Exercise: The Fitness vs. Fatness
Debate. Med Sci. Sports Exerc. Dec. 152-159.
This study investigated the difference in cardiometabolic
benefits between a 25% energy deficit from calorie
restriction that produces equal change in body
fatness with and without aerobic exercise.
Anton S.D., Martin C.K., Redman L., York-Crowe
E., Heilbronn L.K., Han H., Williamson D.A. (2008).
Ravussin E.: Psychosocial and Behavioral Pre-treatment
Predictors of Weight Loss Outcomes. Eat Weight
Disord.; March; 13:30-37. This study looked at
certain baseline behavioral and psychological
variables to see if any could predict weight and
fat loss in overweight, non-obese individuals
engaged in a six-month calorie restriction trial.
Heilbronn, L.K., de Jonge, et al. (2006). Effect
of 6-month Calorie Restriction on Biomarkers of
Longevity, Metabolic Adaptation, and Oxidative
Stress in Overweight Individuals: a Randomized
Controlled Trial. JAMA 295:1539–1548.
This study is sponsored by the National Institute
of Aging and is designed to examine whether calorie
restriction will increase lifespan in humans as
it does in worms and rodents. The 6-month study
has been completed and the manuscript has been
submitted for publication. The control group lost
1% of body weight (NS), the calorie restriction
group lost 10% of body weight, the calorie restriction/exercise
group lost 10% of body weight and the Health-1
group lost 13.5% of their body weight at the end
of the study. The two calorie restriction groups
still had a decreasing weight at the end of the
study, but the Health-1 and control groups were
maintaining their weight. All three weight loss
groups (including Health-1) decreased resting
metabolic rate 6% below predicted and the core
body temperature dropped compared to the control
group. This is consistent with a reduction of
oxidative stress, and is similar to what is seen
in rodents with calorie restriction.
Richard, B., Asnani, S., Desouza, C., & Fonseca,
V. (2003). Is Weight Gain Inevitable With Thiazolidinediones?
Experience With Very Low Calorie Diets. Curr.
Med. Res. Opin. Tulane University, New Orleans,
LA: Vol 19 (7):609-613.
Patients treated with TZD for type 2 diabetes
usually gain weight. 8 type 2 diabetic patients
on a variety of medications (including TZD’s)
all reported weight gain (above their underlying
obesity). These patients were given a low-calorie
meal replacement of 800 calories per day (HEALTH
ONE) and a mean weight loss of 26 pounds was attained
during a 12 week period. Most discontinued or
reduced their use of medications (including insulin)
and gained glycemic control.
Greenway, F., Ryan, D., Bray G., et al. (1999).
Pharmaceutical Cost Savings Of Treating Obesity
With Weight Loss Medications; Pennington Biomedical
Research Center, Louisiana State University. Obesity
Research, 7(6):523-531.
Used a variety of anorectic/thermogenic weight
loss medications (along with HEALTH ONE) to attain
a 20 pound weight loss with Type II Diabetics.
Concluded that considerable cost savings were
attained with reduction of medications used to
control blood sugar. Also, attributed the health
status improvement and cost savings to weight
loss and not to any specific medication regimen
employed.
Greenway, F. (1999). Obesity Medications And
The Treatment Of Type 2 Diabetes. Diabetes Technology
& Therapeutics, 1(3): 277-287.
Major review of medications used in the treatment
of obesity and obesity related Type 2 Diabetes.
Concluded that weight loss formulas of 800 cal/d
are far more efficacious for initial weight loss
and metabolic control; medications are best utilized
in maintaining weight loss.
Henry, R., Medallier, S. Metabolic Effect Of
Weight Loss On Glucose Metabolism And Insulin
Action In Skeletal Muscle And Adipose Tissue Of
Obese Type-2 Diabetics And Non-Diabetics; UC San
Diego VA-Medical Center. Unpublished Results*
SPECIFIC AIMS: To determine in vivo and in vitro
metabolic effects of weight loss on
glucose metabolism and insulin action in skeletal
muscle and adipose tissue in obese non-diabetic
and type-2 diabetic subjects
|
